Dear Editor,
We are grateful for Dr. Park and Dr. Yu’s insightful comments on our recent publication, “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” [
1,
2]. Their editorial highlights the critical need to tackle the rising prevalence of steatotic liver disease (SLD), especially within the challenging backdrop of the coronavirus disease 2019 (COVID-19) pandemic. The pandemic has posed unique challenges to public health and worsened existing health conditions, including chronic liver diseases [
3].
As global obesity rates climb, the prevalence of SLD also increases, leading to significant complications such as liver cirrhosis and hepatocellular carcinoma (HCC) and an increase in mortality [
4,
5]. Within SLD, several subcategories exist, notably metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) [
6]. The current prevalence of SLD varies among diverse racial groups in the United States, with SLD affecting a significant portion of the adult population. The weighted age-adjusted prevalence of SLD is approximately 35%, and nearly one-third of US adults are reported to have MASLD [
1]. Such prevalences are concerning as MASLD is projected to become a leading contributor to chronic liver disease burden, potentially surpassing other chronic liver diseases in terms of adverse outcomes [
7].
The editorial highlights the importance of recognizing variations in disease prevalence across different racial and ethnic groups [
1,
2]. Notably, Hispanics and non-Hispanic Asians exhibited a higher prevalence of MASLD. This discrepancy is associated with genetic factors such as variations in the PNPLA3 gene, which contribute to hepatic fat accumulation and individual susceptibility to MASLD [
1,
2]. In contrast, non-Hispanic Whites and Hispanics showed elevated prevalences of MetALD and ALD. Non-Hispanic Blacks had a consistently lower prevalence.
The COVID-19 pandemic has drastically impacted the global public health systems, leading to a decline in routine health screenings and management for chronic diseases, including SLD. The COVID-19 era and COVID-19 infection emerged as independent predictors of in-hospital mortality among hospitalizations with cirrhosis and decompensated cirrhosis in the United States [
8]. Additionally, all-cause and HCC-related mortality from ALD and MASLD increased rapidly during the COVID-19 pandemic compared to the pre-pandemic era in the United States [
9,
10]. Pandemic-induced lifestyle changes, such as increased time spent indoors, reduced physical activity [
11], and higher alcohol consumption [
12], contributed to worsening liver health among individuals predisposed to SLD. During this period, individuals at high risk did not receive necessary monitoring or intervention, resulting in a rise in fibrosis progression related to SLD [
1]. The editorial emphasizes that the pandemic significantly disrupted public health efforts, intensifying existing challenges. As healthcare systems focused heavily on combating the pandemic, the management of chronic liver diseases like SLD became a lower priority, underscoring a critical need for establishing robust healthcare strategies to address such conditions in the event of future public health emergencies.
Despite advancements in medications like Resmetirom, which has shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, lifestyle modifications remain the cornerstone of managing SLD. Essential lifestyle modifications include dietary interventions, increased physical activity, and strategies to reduce alcohol consumption. In an era where obesity is often considered an issue of individual responsibility, the editorial advocates for a broader, more supportive approach involving community and healthcare system participation. It emphasizes the need for policies and programs that promote healthier lifestyles, particularly in underserved populations disproportionately affected by SLD. To effectively address the growing burden of SLD, we advocate for a multidisciplinary approach involving healthcare providers, public health officials, researchers, and community organizations. This coordinated effort aims to establish comprehensive care strategies, including regular monitoring, early interventions, and public awareness campaigns. Furthermore, healthcare systems should learn from the COVID-19 pandemic to proactively prepare for future challenges. Formulating policies that ensure high-risk populations remain prioritized during health crises is essential to prevent the deterioration of conditions like SLD and chronic liver disease. With nearly one-third of US adults affected by MASLD, it is crucial for healthcare providers and policymakers to act decisively. Improving liver health outcomes and enhancing the quality of life for affected individuals should be a top priority.
The editorial sheds light on the critical issue of health disparities in the prevalence of SLD across different racial and ethnic groups. It highlights the need for targeted research identifying specific risks and barriers to care faced by underserved populations. Addressing these disparities effectively requires healthcare systems to adapt strategies and ensure equitable access to SLD management. By understanding the complexity of health disparities, the impact of lifestyle modifications, and the importance of community support, the healthcare system can develop more effective strategies for managing SLD.
FOOTNOTES
-
Authors’ contribution
All authors contributed equally to the literature review and manuscript preparation. All authors approved the final version of the manuscript.
-
Conflicts of Interest
The authors have no conflicts to disclose.
Abbreviations
alcohol-related liver disease
metabolic dysfunction-associated steatohepatitis
metabolic dysfunction-associated steatotic liver disease
metabolic dysfunction and alcohol-related steatotic liver disease
nonalcoholic fatty liver disease
REFERENCES
- 1. Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023. Clin Mol Hepatol 2025;31:382-393.
- 2. Park J, Yu SJ. Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”. Clin Mol Hepatol 2025;31:625-627.
- 3. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol 2021;19:1469-1479.e19.
- 4. Konyn P, Ahmed A, Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin Mol Hepatol 2023;29(Suppl):S43-S57.
- 5. Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther 2024;60:33-42.
- 6. Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Clin Mol Hepatol 2023;29:831-843.
- 7. Manikat R, Ahmed A, Kim D. Current epidemiology of chronic liver disease. Gastroenterol Rep (Oxf) 2024;12:goae069.
- 8. Kim D, Perumpail BJ, Wijarnpreecha K, Manikat R, Cholankeril G, Ahmed A. Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States. Aliment Pharmacol Ther 2023;58:218-228.
- 9. Kim D, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A. Trends in etiology-based mortality from chronic liver disease before and during COVID-19 pandemic in the United States. Clin Gastroenterol Hepatol 2022;20:2307-2316.e3.
- 10. Kim D, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A. Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018-2023. Clin Mol Hepatol 2024;30:756-770.
- 11. Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol 2022;20:e1438-e1455.
- 12. Manikat R, Ahmed A, Kim D. The impact of alcohol consumption and addiction on liver transplantation programs in the COVID-19 era. Hepat Med 2023;15:141-149.
Citations
Citations to this article as recorded by
- Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Jeayeon Park, Su Jong Yu
Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef - Neonatal liver-derived FTH1-enriched extracellular vesicles attenuate ferroptosis and ameliorate MASLD pathogenesis
Xin Zeng, Wei Jiang, Tian Wu, Lan Li, Fudong Fu, Han Yao, Dongbo Wu
Free Radical Biology and Medicine.2025; 240: 693. CrossRef - Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years
Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna
Journal of Clinical Medicine.2025; 14(21): 7604. CrossRef - Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023
Jialin Wu, Junlong Huang, Shiyu Cao, Yang Lyu, Peiyao Yu, Tiejun Feng, Bonan Chen, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Ka Fai To, Wei Kang
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
, Pojsakorn Danpanichkul2, Karn Wijarnpreecha3,4, George Cholankeril5, Rohit Loomba6, Aijaz Ahmed1
